

Russ Altman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9028797/publications.pdf>

Version: 2024-02-01

117
papers

7,483
citations

94433

37
h-index

62596

80
g-index

140
all docs

140
docs citations

140
times ranked

13962
citing authors

#	ARTICLE	IF	CITATIONS
1	Challenges and opportunities in network-based solutions for biological questions. <i>Briefings in Bioinformatics</i> , 2022, 23, .	6.5	10
2	Construction of disease-specific cytokine profiles by associating disease genes with immune responses. <i>PLoS Computational Biology</i> , 2022, 18, e1009497.	3.2	5
3	Pharmacogenetics at Scale: An Analysis of the UK Biobank. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 1528-1537.	4.7	78
4	Modeling drug response using network-based personalized treatment prediction (NetPTP) with applications to inflammatory bowel disease. <i>PLoS Computational Biology</i> , 2021, 17, e1008631.	3.2	5
5	Large-scale labeling and assessment of sex bias in publicly available expression data. <i>BMC Bioinformatics</i> , 2021, 22, 168.	2.6	12
6	Opportunities and challenges for the computational interpretation of rare variation in clinically important genes. <i>American Journal of Human Genetics</i> , 2021, 108, 535-548.	6.2	40
7	Analyzing the vast coronavirus literature with CoronaCentral. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	7.1	22
8	PhenClust, a standalone tool for identifying trends within sets of biological phenotypes using semantic similarity and the Unified Medical Language System metathesaurus. <i>JAMIA Open</i> , 2021, 4, oaab079.	2.0	3
9	Genomewide Association Studies in Pharmacogenomics. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 637-648.	4.7	38
10	Leveraging the Cell Ontology to classify unseen cell types. <i>Nature Communications</i> , 2021, 12, 5556.	12.8	21
11	Quantifying the Severity of Adverse Drug Reactions Using Social Media: Network Analysis. <i>Journal of Medical Internet Research</i> , 2021, 23, e27714.	4.3	6
12	Pharmacogenomics Clinical Annotation Tool (Pharm<scp>CAT</scp>). <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 203-210.	4.7	65
13	Examining the Use of Real-World Evidence in the Regulatory Process. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 843-852.	4.7	99
14	Scientific considerations for global drug development. <i>Science Translational Medicine</i> , 2020, 12, .	12.4	8
15	Extracting chemical reactions from text using Snorkel. <i>BMC Bioinformatics</i> , 2020, 21, 217.	2.6	10
16	Gaussian embedding for large-scale gene set analysis. <i>Nature Machine Intelligence</i> , 2020, 2, 387-395.	16.0	7
17	Transfer learning enables prediction of CYP2D6 haplotype function. <i>PLoS Computational Biology</i> , 2020, 16, e1008399.	3.2	32
18	Extending TextAE for annotation of non-contiguous entities. <i>Genomics and Informatics</i> , 2020, 18, e15.	0.8	0

#	ARTICLE	IF	CITATIONS
19	Graph Convolutional Neural Networks for Predicting Drug-Target Interactions. <i>Journal of Chemical Information and Modeling</i> , 2019, 59, 4131-4149.	5.4	222
20	Pocket similarity identifies selective estrogen receptor modulators as microtubule modulators at the taxane site. <i>Nature Communications</i> , 2019, 10, 1033.	12.8	22
21	Research Projects Supported by the <sc>University of California, San Francisco</sc>â€™Stanford Center of Excellence in Regulatory Science and Innovation. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 815-818.	4.7	6
22	Essential Characteristics of Pharmacogenomics Study Publications. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 86-91.	4.7	9
23	The association of obesity and coronary artery disease genes with response to SSRIs treatment in major depression. <i>Journal of Neural Transmission</i> , 2019, 126, 35-45.	2.8	27
24	Standardized Biogeographic Grouping System for Annotating Populations in Pharmacogenetic Research. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 1256-1262.	4.7	90
25	Effect of <i><sc>CYP</sc>4F2</i>, <i><sc>VKORC</sc>1</i>, and <i><sc>CYP</sc>2C9</i> in Influencing Coumarin Dose: A Singleâ€™Patient Data Metaâ€™Analysis in More Than 15,000 Individuals. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 1477-1491.	4.7	23
26	Pharmacogenomics in dermatology: tools for understanding gene-drug associations. <i>Seminars in Cutaneous Medicine and Surgery</i> , 2019, 38, E19-E24.	1.6	3
27	Mendelian Disease Associations Reveal Novel Insights into Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 471-481.	1.9	5
28	PharmGKB: A worldwide resource for pharmacogenomic information. <i>Wiley Interdisciplinary Reviews: Systems Biology and Medicine</i> , 2018, 10, e1417.	6.6	205
29	Pharmacogenomics and big genomic data: from lab to clinic and back again. <i>Human Molecular Genetics</i> , 2018, 27, R72-R78.	2.9	28
30	Genome-wide and candidate gene approaches of clopidogrel efficacy using pharmacodynamic and clinical end pointsâ€™Rationale and design of the International Clopidogrel Pharmacogenomics Consortium (ICPC). <i>American Heart Journal</i> , 2018, 198, 152-159.	2.7	24
31	A dynamic map for learning, communicating, navigating and improving therapeutic development. <i>Nature Reviews Drug Discovery</i> , 2018, 17, 150-150.	46.4	43
32	Expanding a radiology lexicon using contextual patterns in radiology reports. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2018, 25, 679-685.	4.4	20
33	Biological and functional relevance of CASP predictions. <i>Proteins: Structure, Function and Bioinformatics</i> , 2018, 86, 374-386.	2.6	12
34	Biomarkers: Delivering on the expectation of molecularly driven, quantitative health. <i>Experimental Biology and Medicine</i> , 2018, 243, 313-322.	2.4	13
35	Challenges for Training Translational Researchers in the Era of Ubiquitous Data. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 103, 171-173.	4.7	6
36	PathFX provides mechanistic insights into drug efficacy and safety for regulatory review and therapeutic development. <i>PLoS Computational Biology</i> , 2018, 14, e1006614.	3.2	13

#	ARTICLE	IF	CITATIONS
37	The Pioglitazone Trek via Human PPAR Gamma: From Discovery to a Medicine at the FDA and Beyond. <i>Frontiers in Pharmacology</i> , 2018, 9, 1093.	3.5	31
38	Data-driven human transcriptomic modules determined by independent component analysis. <i>BMC Bioinformatics</i> , 2018, 19, 327.	2.6	25
39	Association of the Polygenic Scores for Personality Traits and Response to Selective Serotonin Reuptake Inhibitors in Patients with Major Depressive Disorder. <i>Frontiers in Psychiatry</i> , 2018, 9, 65.	2.6	38
40	Machine learning in chemoinformatics and drug discovery. <i>Drug Discovery Today</i> , 2018, 23, 1538-1546.	6.4	630
41	Systematic target function annotation of human transcription factors. <i>BMC Biology</i> , 2018, 16, 4.	3.8	12
42	Reversals and limitations on high-intensity, life-sustaining treatments. <i>PLoS ONE</i> , 2018, 13, e0190569.	2.5	7
43	The Pharmacogenomics Research Network Translational Pharmacogenetics Program: Outcomes and Metrics of Pharmacogenetic Implementations Across Diverse Healthcare Systems. <i>Clinical Pharmacology and Therapeutics</i> , 2017, 102, 502-510.	4.7	117
44	Artificial intelligence (AI) systems for interpreting complex medical datasets. <i>Clinical Pharmacology and Therapeutics</i> , 2017, 101, 585-586.	4.7	45
45	Pharmacogenomics-Based Point-of-Care Clinical Decision Support Significantly Alters Drug Prescribing. <i>Clinical Pharmacology and Therapeutics</i> , 2017, 102, 859-869.	4.7	68
46	Working toward precision medicine: Predicting phenotypes from exomes in the Critical Assessment of Genome Interpretation (CAGI) challenges. <i>Human Mutation</i> , 2017, 38, 1182-1192.	2.5	39
47	Development of an automated assessment tool for MedWatch reports in the FDA adverse event reporting system. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2017, 24, 913-920.	4.4	26
48	Decaying relevance of clinical data towards future decisions in data-driven inpatient clinical order sets. <i>International Journal of Medical Informatics</i> , 2017, 102, 71-79.	3.3	80
49	Shallow Representation Learning via Kernel PCA Improves QSAR Modelability. <i>Journal of Chemical Information and Modeling</i> , 2017, 57, 1859-1867.	5.4	13
50	3D deep convolutional neural networks for amino acid environment similarity analysis. <i>BMC Bioinformatics</i> , 2017, 18, 302.	2.6	106
51	Opportunities for developing therapies for rare genetic diseases: focus on gain-of-function and allostery. <i>Orphanet Journal of Rare Diseases</i> , 2017, 12, 61.	2.7	34
52	Flexible Analog Search with Kernel PCA Embedded Molecule Vectors. <i>Computational and Structural Biotechnology Journal</i> , 2017, 15, 320-327.	4.1	4
53	Predicting inpatient clinical order patterns with probabilistic topic models vs conventional order sets. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2017, 24, 472-480.	4.4	54
54	Towards Clinical Bioinformatics: Redux 2015. <i>Yearbook of Medical Informatics</i> , 2016, 25, S6-S7.	1.0	1

#	ARTICLE	IF	CITATIONS
55	Human induced pluripotent stem cellâ€‘derived cardiomyocytes recapitulate the predilection of breast cancer patients to doxorubicin-induced cardiotoxicity. <i>Nature Medicine</i> , 2016, 22, 547-556.	30.7	573
56	Computing disease incidence, prevalence and comorbidity from electronic medical records. <i>Journal of Biomedical Informatics</i> , 2016, 63, 108-111.	4.3	24
57	Populationâ€‘specific singleâ€‘nucleotide polymorphism confersâ€‘increased risk of venous thromboembolism in African Americans. <i>Molecular Genetics & Genomic Medicine</i> , 2016, 4, 513-520.	1.2	7
58	Response to Open Peer Commentaries on â€‘Human Germline CRISPR-Cas Modification: Toward a Regulatory Frameworkâ€‘. <i>American Journal of Bioethics</i> , 2016, 16, W1-W2.	0.9	1
59	Estimation of Maximum Recommended Therapeutic Dose Using Predicted Promiscuity and Potency. <i>Clinical and Translational Science</i> , 2016, 9, 311-320.	3.1	7
60	A research roadmap for next-generation sequencing informatics. <i>Science Translational Medicine</i> , 2016, 8, 335ps10.	12.4	37
61	OrderRex: clinical order decision support and outcome predictions by data-mining electronic medical records. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2016, 23, 339-348.	4.4	42
62	Constraints on Biological Mechanism from Disease Comorbidity Using Electronic Medical Records and Database of Genetic Variants. <i>PLoS Computational Biology</i> , 2016, 12, e1004885.	3.2	27
63	Sequence to Medical Phenotypes: A Framework for Interpretation of Human Whole Genome DNA Sequence Data. <i>PLoS Genetics</i> , 2015, 11, e1005496.	3.5	23
64	Evidence for Clinical Implementation of Pharmacogenomics in Cardiac Drugs. <i>Mayo Clinic Proceedings</i> , 2015, 90, 716-729.	3.0	44
65	Neurotoxicity of Generic Anesthesia Agents in Infants and Children. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 1515.	7.4	48
66	Human Germline CRISPR-Cas Modification: Toward a Regulatory Framework. <i>American Journal of Bioethics</i> , 2015, 15, 25-29.	0.9	53
67	Unmet needs: Research helps regulators do their jobs. <i>Science Translational Medicine</i> , 2015, 7, 315ps22.	12.4	15
68	Enabling the Curation of Your Pharmacogenetic Study. <i>Clinical Pharmacology and Therapeutics</i> , 2015, 97, 116-119.	4.7	6
69	Using â€‘Big Dataâ€‘to Dissect Clinical Heterogeneity. <i>Circulation</i> , 2015, 131, 232-233.	1.6	28
70	Predicting Cancer Drug Response: Advancing the DREAM. <i>Cancer Discovery</i> , 2015, 5, 237-238.	9.4	11
71	Relating Essential Proteins to Drug Side-Effects Using Canonical Component Analysis: A Structure-Based Approach. <i>Journal of Chemical Information and Modeling</i> , 2015, 55, 1483-1494.	5.4	34
72	Variations in the Binding Pocket of an Inhibitor of the Bacterial Division Protein FtsZ across Genotypes and Species. <i>PLoS Computational Biology</i> , 2015, 11, e1004117.	3.2	21

#	ARTICLE	IF	CITATIONS
73	The International SSRI Pharmacogenomics Consortium (ISPC): a genome-wide association study of antidepressant treatment response. <i>Translational Psychiatry</i> , 2015, 5, e553-e553.	4.8	107
74	Potential Adverse Effects of Anesthesia in Children—Reply. <i>JAMA - Journal of the American Medical Association</i> , 2015, 314, 409.	7.4	2
75	High Resolution Prediction of Calcium-Binding Sites in 3D Protein Structures Using FEATURE. <i>Journal of Chemical Information and Modeling</i> , 2015, 55, 1663-1672.	5.4	13
76	Personalization in practice. <i>Science</i> , 2015, 350, 282-283.	12.6	20
77	Genomics in the clinic: ethical and policy challenges in clinical next-generation sequencing programs at early adopter USA institutions. <i>Personalized Medicine</i> , 2015, 12, 269-282.	1.5	3
78	Learning the Structure of Biomedical Relationships from Unstructured Text. <i>PLoS Computational Biology</i> , 2015, 11, e1004216.	3.2	36
79	Ranking Adverse Drug Reactions With Crowdsourcing. <i>Journal of Medical Internet Research</i> , 2015, 17, e80.	4.3	35
80	High Precision Prediction of Functional Sites in Protein Structures. <i>PLoS ONE</i> , 2014, 9, e91240.	2.5	15
81	Environmental and State-Level Regulatory Factors Affect the Incidence of Autism and Intellectual Disability. <i>PLoS Computational Biology</i> , 2014, 10, e1003518.	3.2	48
82	Knowledge-based Fragment Binding Prediction. <i>PLoS Computational Biology</i> , 2014, 10, e1003589.	3.2	32
83	Clinical Interpretation and Implications of Whole-Genome Sequencing. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 1035.	7.4	398
84	Guidelines for investigating causality of sequence variants in human disease. <i>Nature</i> , 2014, 508, 469-476.	27.8	1,130
85	Interpreting the CYP2D6 Results From the International Tamoxifen Pharmacogenetics Consortium. <i>Clinical Pharmacology and Therapeutics</i> , 2014, 96, 144-146.	4.7	14
86	Personal Genomic Measurements: The Opportunity for Information Integration. <i>Clinical Pharmacology and Therapeutics</i> , 2013, 93, 21-23.	4.7	26
87	Challenges in the Pharmacogenomic Annotation of Whole Genomes. <i>Clinical Pharmacology and Therapeutics</i> , 2013, 94, 211-213.	4.7	23
88	Chapter 7: Pharmacogenomics. <i>PLoS Computational Biology</i> , 2012, 8, e1002817.	3.2	57
89	Data-Driven Prediction of Drug Effects and Interactions. <i>Science Translational Medicine</i> , 2012, 4, 125ra31.	12.4	610
90	Translational Bioinformatics: Linking the Molecular World to the Clinical World. <i>Clinical Pharmacology and Therapeutics</i> , 2012, 91, 994-1000.	4.7	43

#	ARTICLE	IF	CITATIONS
91	Introduction to Translational Bioinformatics Collection. <i>PLoS Computational Biology</i> , 2012, 8, e1002796.	3.2	12
92	A novel signal detection algorithm for identifying hidden drug-drug interactions in adverse event reports. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2012, 19, 79-85.	4.4	165
93	Pharmacogenomics: will the promise be fulfilled?. <i>Nature Reviews Genetics</i> , 2011, 12, 69-73.	16.3	29
94	Pharmacogenomics: "Noninferiority" Is Sufficient for Initial Implementation. <i>Clinical Pharmacology and Therapeutics</i> , 2011, 89, 348-350.	4.7	85
95	Detecting Drug Interactions From Adverse-Event Reports: Interaction Between Paroxetine and Pravastatin Increases Blood Glucose Levels. <i>Clinical Pharmacology and Therapeutics</i> , 2011, 90, 133-142.	4.7	183
96	2010 Translational bioinformatics year in review. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2011, 18, 358-366.	4.4	10
97	Using Multiple Microenvironments to Find Similar Ligand-Binding Sites: Application to Kinase Inhibitor Binding. <i>PLoS Computational Biology</i> , 2011, 7, e1002326.	3.2	60
98	Using Pre-existing Microarray Datasets to Increase Experimental Power: Application to Insulin Resistance. <i>PLoS Computational Biology</i> , 2010, 6, e1000718.	3.2	11
99	Generating Genome-Scale Candidate Gene Lists for Pharmacogenomics. <i>Clinical Pharmacology and Therapeutics</i> , 2009, 86, 183-189.	4.7	75
100	Direct-to-Consumer Genetic Testing: Failure Is Not an Option. <i>Clinical Pharmacology and Therapeutics</i> , 2009, 86, 15-17.	4.7	24
101	Robust recognition of zinc binding sites in proteins. <i>Protein Science</i> , 2008, 17, 54-65.	7.6	88
102	An XML-based interchange format for genotype-phenotype data. <i>Human Mutation</i> , 2008, 29, 212-219.	2.5	6
103	Commentaries on "Informatics and medicine: from molecules to populations". <i>Methods of Information in Medicine</i> , 2008, 47, 296-317.	1.2	4
104	Genetic nondiscrimination legislation: a critical prerequisite for pharmacogenomics data sharing. <i>Pharmacogenomics</i> , 2007, 8, 519-519.	1.3	9
105	The Education Potential of the Pharmacogenetics and Pharmacogenomics Knowledge Base (PharmGKB). <i>Clinical Pharmacology and Therapeutics</i> , 2007, 82, 472-475.	4.7	16
106	Using surface envelopes to constrain molecular modeling. <i>Protein Science</i> , 2007, 16, 1266-1273.	7.6	0
107	Local Kinetic Measures of Macromolecular Structure Reveal Partitioning among Multiple Parallel Pathways from the Earliest Steps in the Folding of a Large RNA Molecule. <i>Journal of Molecular Biology</i> , 2006, 358, 1179-1190.	4.2	46
108	Structural characterization of proteins using residue environments. <i>Proteins: Structure, Function and Bioinformatics</i> , 2005, 61, 741-747.	2.6	24

#	ARTICLE	IF	CITATIONS
109	Time to Organize the Bioinformatics Resourceome. PLoS Computational Biology, 2005, 1, e76.	3.2	70
110	An 'Omics' view of drug development. Drug Development Research, 2004, 62, 81-85.	2.9	8
111	Using surface envelopes for discrimination of molecular models. Protein Science, 2004, 13, 15-24.	7.6	5
112	Title is missing!. Machine Learning, 2003, 52, 119-145.	5.4	6
113	WebFEATURE: an interactive web tool for identifying and visualizing functional sites on macromolecular structures. Nucleic Acids Research, 2003, 31, 3324-3327.	14.5	79
114	Complexities of Managing Biomedical Information. OMICS A Journal of Integrative Biology, 2003, 7, 127-129.	2.0	1
115	Genetic sequence data for pharmacogenomics. Current Opinion in Drug Discovery & Development, 2003, 6, 297-303.	1.9	2
116	Challenges for Biomedical Informatics and Pharmacogenomics. Annual Review of Pharmacology and Toxicology, 2002, 42, 113-133.	9.4	93
117	The Interactions Between Clinical Informatics and Bioinformatics: A Case Study. Journal of the American Medical Informatics Association: JAMIA, 2000, 7, 439-443.	4.4	41